RyMed Technologies, LLC
Protecting your patient from CLABSI with the ONLY Needleless Connector with Chlorhexidine and Silver
Protecting your patient from CLABSI with the ONLY Needleless Connector with Chlorhexidine and Silver
RyMed Technologies, LLC is a company specializing in the development and marketing of innovative safety products for intravenous catheter management. Founded in 1994 and based in the United States, RyMed's flagship product is the InVision-Plus® needleless connector with Neutral Advantage™ Technology, designed to reduce catheter-related bloodstream infections (CR-BSI) and intraluminal thrombotic catheter occlusions. The company also offers the InVision-Plus CS, the only needleless connector treated with Chlorhexidine and Silver, aiming to maximize catheter protection. With the representation of PICC Guard, RyMed addresses concerns related to the opioid epidemic while focusing on patient-centered care. The company secured a $6.13M Debt Financing investment on 02 August 2012. RyMed operates primarily in the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $6.13M | - | 02 Aug 2012 | |
| Debt Financing | $800.00K | - | 18 Feb 2011 | |
| Venture Round | $160.00K | - | 19 Aug 2010 | |
| Venture Round | $842.50K | - | 13 Aug 2009 |
We care about your data, and we'd love to use cookies make your experience better.
